secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2022-12-01T23:59:59+00:00
Accession:  0001104659-22-123704
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 3.03, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Pharmaceuticals effects 1-for-40 reverse stock split to regain Nasdaq bid price compliance
--------------------------------------------------------------------------------

- Reverse split at 1-for-40 approved by shareholders on Nov 30, 2022; board set ratio same day.
- Effective at 5:00 PM ET on Dec 1, 2022; split-adjusted trading begins Dec 2 under symbol ELOX.
- Goal is to raise per-share price above Nasdaq's minimum $1 bid requirement and maintain listing.
- Fractional shares will be cashed out at closing price on Nov 30; no fractional shares issued.
- Proportionate adjustments made to outstanding equity awards, warrants, and equity plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922123704/0001104659-22-123704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465922123704/tm2231725d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-123704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer